Beinaglutide
Also known as: B-GLP-1, Bei Na Lu Tai, Beigelu, Beinaglutide, GLP-1 (7-36) amide (recombinant human), rhGLP-1
Source Beinaglutide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Beinaglutide is a long‑acting GLP‑1 analog used to improve glycaemic control in adults with type 2 diabetes; it is administered subcutaneously once daily.
Mechanism of Action
Activates the glucagon‑like peptide‑1 (GLP‑1) receptor, enhancing glucose‑dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying.
Routes of Administration
Goals & Uses
- Cardiovascular risk reductionCardiovascularLow
- Weight reduction / anti-obesityMetabolicHigh
- Weight reductionMetabolicModerate
- Glycemic control in type 2 diabetesMetabolicHigh
- Glycaemic controlDiabetesHigh
- Beta-cell preservationMetabolicModerate
Contraindications
- Personal or family history of medullary thyroid carcinomaOncologicHigh
- Severe gastrointestinal diseaseGastrointestinalModerate
- Multiple endocrine neoplasia syndrome type 2 (MEN2)OncologicHigh
- Severe renal impairmentOrganModerateKidney function concerns
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Multiple endocrine neoplasia type 2OncologyHigh
- Medullary thyroid carcinomaOncologyHigh
- Type 1 diabetes mellitusEndocrineModerate
Adverse Effects
- PancreatitisGastrointestinalRareInflammation of the pancreas
- HypoglycemiaMetabolicUncommonAbnormally low blood glucose
- Injection site reactionsLocalCommon
- Hypoglycaemia (with sulfonylureas/insulin)MetabolicUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalCommonForceful expulsion of stomach contents
- DiarrheaGastrointestinalCommonLoose or frequent stools
Drug Interactions
- InsulinModerateMay increase risk of low blood sugar
- Oral medications (general)Low
- WarfarinModerate
- SulfonylureasModerateMay increase risk of low blood sugar
Population Constraints
- PregnancyReproductive SafetyAbsolute
- Pediatric patients (<18 years)AgeRelative
- LactationReproductiveRelative
- Elderly patients (>75 years)AgeRelative
- Pediatric (<18 years)AgeAbsolute
- Pregnant womenReproductiveRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionUnapprovedNo EMA assessment.
- United StatesUnapprovedNot submitted for FDA approval.
- United KingdomUnapprovedNot authorized by MHRA.
Approved in China (2020) for type 2 diabetes; not approved in the United States, European Union, or United Kingdom.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Beinaglutide?
Beinaglutide is a long‑acting GLP‑1 analog used to improve glycaemic control in adults with type 2 diabetes; it is administered subcutaneously once daily.
What is Beinaglutide used for?
Beinaglutide is educationally associated with: Cardiovascular risk reduction, Weight reduction / anti-obesity, Weight reduction, Glycemic control in type 2 diabetes, Glycaemic control, Beta-cell preservation. Educational only — not medical advice.
How is Beinaglutide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Beinaglutide?
Reported adverse effects include: Pancreatitis, Hypoglycemia, Injection site reactions, Hypoglycaemia (with sulfonylureas/insulin), Nausea, Vomiting, Diarrhea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Beinaglutide?
Recorded contraindications: Personal or family history of medullary thyroid carcinoma, Severe gastrointestinal disease, Multiple endocrine neoplasia syndrome type 2 (MEN2), Severe renal impairment, Pregnancy, Multiple endocrine neoplasia type 2, Medullary thyroid carcinoma, Type 1 diabetes mellitus. Consult a qualified clinician before use.